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Abstract
3D-QSAR and molecular docking methods were performed on a set of 74 benzimidazole derivatives previously studied as
activators of the AMP-activated protein kinase (AMPK), a protein that plays a key role in the regulation of cellular energy balance.
Relative enzyme activity (REA) of 74 compounds was quantitatively modelled using multiple linear regression (MLR) and neuronal
networks (NN). The proposed QSAR model provided statistically significant results (rMLR = 0.89; rNN = 0.95 and rCV = 0.90) and
was validated using the leave-one-out method. The general binding mode of benzimidazole derivatives to the AMPK binding site
was explored using molecular docking, with a focus on the most active molecules of our set, compounds 19  and 25.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: REA (relative enzyme activity); Benzimidazole derivatives; Quantitative structure–activity relationship (QSAR); Multiple linear regres-
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2.3.  Software  used  in  analysisReferences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.  Introduction
AMP-activated protein kinase (AMPK) is a highly
onserved sensor of cellular energy status and a well-
nown regulator of cell metabolism. The protein is a
eterotrimeric triangle complex that consists of three
ubunits, including a catalytic   subunit and two regu-
atory subunits,   and . Each subunit exits as one of
everal isoforms in human AMPK, including 1, 2,
1, 2, 1, 2 and 3 (Fig. 1), and all of the 12 pos-
ible different AMPK trimer isoforms are formed and
istributed in different tissues [1–3]. The threonine-172
Thr172) within the   subunit is the major site phos-
horylated during activation of AMPK. The   subunit,
hich contains a binding site for glycogen, is thought
o stabilize the trimeric complex. The   subunit carries
our cystathionine--synthase (CBS) domains and is the
ajor binding site of AMP.
An AMP analogue, AICA-ribose (AICAR), is a
elective activator of AMPK and has been shown to
mprove glucose tolerance and lipid profiles in an insulin-
esistance rat model [4]. AMPK is activated by a decrease
n the ratio of ATP to AMP, a cellular state that leads to
nhibition of ATP-consuming metabolic pathways and
ctivation of energy-producing pathways [5]. In previ-
us studies of Kahn [6] and Viollet [7], AMPK activation
as demonstrated to play an important role in regulat-
ng insulin secretion and is considered to be a central
ediator in the treatment of type 2 diabetes mellitus.
In this work, we attempt to establish a quantitative
tructure–activity relationship (QSAR) between the ben-
imidazole structure and AMPK receptor by studying a
eries of 74 substituted benzimidazole derivatives. We
ropose a quantitative model and attempt to interpret the . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
activity of the compounds using the statistical analyses.
Multiple linear regression (MLR) is employed to select
the descriptors used as the input parameters for the neural
network (NN), and leave-one-out cross validation (CV)
is performed to validate the proposed model. Finally, to
better understand the relationship between structure and
activity, we use molecular docking.
2.  Materials  and  methods
2.1.  Experimental  data
For the present molecular modelling study, a set of 74
benzimidazole derivatives was obtained from published
work of Julie and co-workers [8]. The structures of 74
benzimidazole derivatives are listed in Table 1 with their
observed activities (REA).
2.2.  Descriptors  generation
To obtain a QSAR model, the activity of com-
pounds must be represented by molecular descriptors
[9]. The process of calculating the molecular descrip-
tors is described as follows. First, all molecules were
drawn and pre-optimized in the ACDLAB.12.0 program
using an MM2 force field. Then the resulting geometries
formed the inputs for Chem3D  Ultra  software to cal-
culate steric, thermodynamic and electronic descriptors
(Table 2).(a) ACD/ChemSketch: a drawing package that allowed


























List of benzimidazole derivatives with their corresponding structures and observed activities (REA).
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Fig. 1. Catalytic subunits of AMPK () and two regulatory subunits ( and ).
Table 2
Molecular descriptor categories chosen in this study.
Category of descriptors Electronic Steric Thermodynamic
Descriptors Highest occupied molecular orbital
energy (EHOMO)















ables with a single, continuous dependent variable [18].molecular properties (molecular weight, density,
molar refractivity, parachor) [10].
(b) ChemDraw  Ultra  ver  8.0: used to optimize molecu-
lar geometries and to calculate molecular descriptors
(steric, thermodynamic, and electronic) [11].
(c) Systat13: used to perform MLR analysis (descrip-
tors selection was based on statistical calculations
P < 0.05) [12].
(d) Autodock  Vina: a new program for virtual screening
and docking in drug discovery, offering multi-core
capability, high performance, enhanced accuracy
and ease of use. Vina uses the same PDBQT molec-
ular structure file format used by AutoDock for its
input and output, and PDBQT files can be generated
and viewed using MGL Tools [13].
(e) Matlab  7.8: used to perform NN analysis (neural
network) [14].
(f) Pymol  software: used to display the protein struc-
ture (obtained from the PDB), which is the receptor
for the studied molecules [15].
(g) Discovery  Studio  3.5: typically used in the devel-
opment of novel therapeutic medicines, includingsity (D)
x refraction (IR)
rizability (Pol)
small-molecules, therapeutic antibodies, vaccines
and synthetic enzymes [16]. In this work, it was used
to visualize the ligand–protein interactions.
2.4.  Principal  component  analysis  (PCA)
PCA  is a method of family data analysis that consists
of two types of analysis. In the first case, the analysis is
performed on the correlation matrix, whereas the analy-
sis is performed on the covariance matrix in the second
case. A special feature of the PCA is to help visualize
and classify the interaction between variables [17].
2.5.  Multiple  linear  regression  (MLR)
Multiple linear regression analysis is an extension of
simple linear regression analysis and is used to evaluate
the association between two or more independent vari-The regression equation takes the form:
YMLR =  a0 +
n∑
i=1
ai ∗  Ci







































Fig. 2. Structure of AMPK protein taken from the PDB website and
displayed in Pymol software. (A) Isoform 2, (B) isoform 1, (E)
= REA
λ −  1
λ
and λ  =  −0.5;N. Naceiri Mrabti, M. Elhallaoui / Journal
here YMLR: dependent variable; a0: regression constant
r intercept; ai: regression coefficient; Ci: independent
ariable.
In this study, we used the method of stepwise regres-
ion [19]. The descriptors proposed by MLR in the
quation were used as the input parameters in the neural
etwork (NN).
.6.  Neural  network
All of the feed-forward NNs used in this paper
re three-layer networks in which the input layer con-
ains four neurons, representing the relevant descriptors
btained by MLR techniques. Although there are neither
heoretical nor empirical rules to determine the number
f hidden layers or the number of neuron layers, one
idden layer seems to be sufficient in most chemical
pplications of NN [20]. Some authors have proposed
 parameter ρ, which allows the determination of the
umber of hidden neurons and plays a major role in
etermining the best NN architecture. The parameter is
efined as follows:
 = Number of data points in the training set
Sum of the number of connections in the NN
To avoid overfitting or underfitting, it is best to use
 ρ  value in the range 1.8 < ρ  < 2.3 [21]. The NN used
n this work was formed by three hidden neurons, and
he output layer represents the calculated activity values
NN.
.7.  Cross  validation
Cross validation is a method used to measure the pre-
ictive ability of a model and draw attention to whether
he model is over-fitted. Over-fitting refers to the phe-
omenon in which a predictive model describes the
elationship between predictors and responses but may
ubsequently fail to provide valid predictions for new
ompounds. The process of CV begins with the removal
f one (leave-one-out LOO) or a group (leave-many-
ut LMO) of compounds to create a temporary test set
rom the training set. A CV model is created from the
emaining data points using the descriptors from the orig-
nal model and tested for its ability to correctly predict
he activity on the compounds removed from the set. In
his paper we used the LOO method to test the QSAR
odel [22].isoform 1.
2.8.  Molecular  docking
Docking is a molecular modeling method that predicts
the preferred orientation of a ligand molecule when bind-
ing to a receptor, such as a protein. The process involves
optimization to find the best position of a ligand in a
receptor binding site [23]. Molecular docking is widely
used in virtual screening, and some successful cases have
been reported. The docking model and scoring functions
have been extensively studied in recent years, and many
scoring functions have been proposed [24]. In this work,
we used the Autodock  Vina  program to carry out the
molecular docking studies.
The crystal structure of AMPK (Fig. 2) was retrieved
from the RCSB Protein Data Bank (PDB code: 2U8Q).
The docked ligands were built and optimized with
ChemDraw 3D Ultra 8.0 software, and the resulting com-
plexes of molecular docking were visualized in Pymol
and Discovery  3.5  software [14].
3.  Results  and  discussion
3.1.  Data  set  for  analysis
The QSAR analysis was performed using the experi-
mental REA values of the 74 compounds as reported by
Julie et al. [8]. The values for the biological activity of
the 74 compounds were converted using the COX–BOX
method [25] in Minitab7 software [26] and used in the
following equation.



























Values of the 15 chemical descriptors calculated for the 74 compounds.
MW RM IR D R ELUMO EHOMO Tindx ClsC IW Log P Par ST Pol EVDW YExp
600.40 90.73 1.59 1.09 5.00 −0.22 −7.18 20,851.00 22.00 990.00 5.05 696.00 45.00 35.97 12.95 0.1677
619.44 89.46 1.63 1.11 5.00 −0.32 −7.11 7968.00 22.00 990.00 4.74 663.00 47.30 35.46 11.09 0.2908
581.36 91.83 1.55 1.04 5.00 −0.13 −7.15 7968.00 22.00 990.00 1.36 722.70 39.80 36.40 15.00 0.2908
540.40 65.06 1.61 1.11 5.00 0.48 −7.10 3718.00 16.00 459.00 1.38 490.10 45.30 25.79 8.74 0.2908
521.36 66.26 1.54 1.03 5.00 0.48 −7.17 3718.00 16.00 459.00 1.06 530.60 40.20 26.26 7.12 0.2908
630.70 82.90 1.67 1.17 6.00 −0.16 −7.80 6886.00 20.00 857.00 2.06 593.90 50.30 32.86 11.34 0.2035
630.70 82.90 1.67 1.17 5.00 −0.30 −7.58 6574.00 20.00 817.00 1.06 593.90 50.30 32.86 11.20 0.2660
681.67 75.69 1.61 1.15 5.00 0.42 −7.74 5707.00 19.00 718.00 1.29 551.80 40.40 30.00 6.74 0.2817
660.09 80.50 1.64 1.21 5.00 0.34 −7.78 5628.00 19.00 718.00 1.29 575.90 45.00 31.91 7.13 0.2735
601.15 76.98 1.62 1.14 5.00 −0.25 −7.27 5670.00 19.00 703.00 1.20 578.70 47.40 30.51 7.83 0.2817
684.46 87.73 1.98 1.22 6.00 −0.39 −7.33 7616.00 22.00 945.00 1.18 631.90 54.50 34.78 11.86 0.2817
575.46 74.52 1.58 1.06 5.00 −0.68 −7.36 5236.00 18.00 650.00 1.00 568.80 41.50 29.54 15.13 0.3010
574.94 74.33 1.58 1.07 5.00 0.41 −7.63 4816.00 18.00 596.00 1.10 568.30 42.40 29.46 8.90 0.3010
547.94 74.25 1.58 1.07 5.00 0.50 −7.62 5166.00 18.00 641.00 1.17 558.80 39.10 29.43 9.00 0.2817
536.67 69.70 1.59 1.09 5.00 0.41 −7.63 4200.00 17.00 519.00 1.05 528.50 43.20 27.63 7.95 0.3010
599.71 73.25 1.67 1.64 4.00 −0.85 −7.42 7012.00 16.00 423.00 1.42 528.00 51.70 29.03 13.68 0.2660
620.28 81.35 1.61 1.12 5.00 −0.22 −7.22 5978.00 20.00 740.00 1.11 623.10 48.90 32.25 11.86 0.2908
592.65 86.12 1.60 1.11 5.00 −0.24 −7.23 3249.00 21.00 870.00 1.00 655.90 46.70 34.14 12.84 0.3259
593.02 92.86 1.56 1.02 6.00 −0.36 −7.71 21,345.00 22.00 1094.00 5.18 727.40 40.30 36.81 19.22 0.1384
567.64 72.22 1.64 1.17 5.00 −0.27 −7.28 12,462.00 18.00 634.00 4.38 538.60 50.90 28.63 10.67 0.1554
529.13 60.34 1.61 1.12 4.00 −0.70 −7.40 2942.00 15.00 361.00 1.09 452.40 44.90 23.92 12.56 0.3126
603.85 60.35 1.56 1.09 4.00 −0.20 −7.34 6085.00 15.00 361.00 1.06 478.20 43.00 23.92 9.79 0.2908
635.69 84.93 1.63 1.13 5.00 −0.69 −7.24 12,628.00 21.00 895.00 4.93 625.70 46.10 33.67 19.11 0.1592
635.69 84.93 1.63 1.13 6.00 −0.80 −7.18 7204.00 21.00 1003.00 1.63 625.70 46.10 33.67 18.96 0.2908
635.69 84.93 1.63 1.13 6.00 −0.73 −7.42 16,179.00 21.00 949.00 5.03 625.70 46.10 34.01 18.96 0.1376
642.48 77.23 1.61 1.18 5.00 −0.66 −7.15 7624.00 20.00 776.00 1.05 579.70 45.80 30.61 9.79 0.3126
648.80 84.92 1.61 1.12 6.00 −0.84 −7.44 7896.00 22.00 1032.00 4.79 632.90 45.00 33.66 12.19 0.2908
699.39 83.32 1.65 1.21 5.00 −0.80 −7.23 8457.00 20.00 776.00 4.62 608.20 49.50 33.03 16.22 0.1731
659.48 89.76 1.62 1.12 6.00 −0.67 −7.11 2893.00 22.00 1032.00 1.12 663.40 44.80 35.58 7.79 0.3600
658.23 94.38 1.62 1.12 6.00 −0.56 −7.33 7906.00 23.00 1251.00 1.07 701.10 46.60 37.41 9.79 0.2908
646.96 89.65 1.62 1.13 6.00 −0.58 −7.35 8528.00 22.00 1062.00 1.19 663.40 46.40 35.54 17.80 0.2817
601.45 68.03 1.63 1.44 4.00 −0.90 −7.16 3292.00 16.00 432.00 1.01 502.90 48.10 26.97 13.04 0.3259
629.36 89.69 1.61 1.13 5.00 −0.23 −7.21 15,965.00 22.00 990.00 5.01 675.90 45.80 35.55 15.80 0.1476
644.66 86.68 1.61 1.18 5.00 −0.30 −7.28 7658.00 22.00 990.00 1.04 656.20 46.80 34.36 9.79 0.3010
637.11 94.30 1.60 1.11 5.00 −0.23 −7.21 8873.00 23.00 1113.00 1.09 716.00 44.30 37.38 14.54 0.3010

























685.94 91.28 1.63 1.21 5.00 −0.18 −7.14 8718.00 23.00 1129.00 2.37 690.90 52.40 36.18 9.58 0.2817
653.06 95.30 1.63 1.14 5.00 −0.22 −7.31 9249.00 23.00 1161.00 5.17 715.90 51.10 37.78 18.33 0.1508
636.60 90.86 1.63 1.14 5.00 −0.70 −7.30 10,520.00 22.00 990.00 4.91 683.00 50.20 36.02 15.44 0.1709
698.27 89.94 1.65 1.12 6.00 0.43 −7.64 10,060.00 22.00 1074.00 3.86 664.30 51.60 35.65 11.51 0.1953
335.40 98.15 1.66 1.26 5.00 −1.12 −7.15 8815.00 25.00 1401.00 1.64 737.20 58.90 38.90 13.76 0.3010
305.42 95.84 1.67 1.19 5.00 −0.22 −7.53 10,026.00 23.00 1111.00 4.43 707.60 57.80 37.99 12.31 0.1709
305.42 95.84 1.67 1.19 6.00 −0.15 −7.25 11,303.00 25.00 1423.00 3.06 707.60 57.80 37.99 14.43 0.1929
347.45 105.87 1.66 1.21 5.00 −0.36 −7.11 5118.00 26.00 1423.00 1.00 785.50 55.80 41.97 11.63 0.3415
304.43 96.42 1.63 1.13 5.00 −0.28 −7.74 9063.00 23.00 1127.00 2.12 719.40 50.00 38.22 13.59 0.2279
304.43 96.42 1.63 1.13 5.00 −0.28 −7.70 8937.00 23.00 1111.00 1.92 719.40 50.00 38.22 13.68 0.2323
320.43 98.28 1.62 1.15 6.00 −0.40 −8.05 16,328.00 24.00 1287.00 5.84 738.40 49.60 38.96 20.69 0.1401
308.39 91.59 1.63 1.19 5.00 −0.57 −7.88 8649.00 23.00 1127.00 1.89 688.90 50.40 36.31 12.67 0.2419
324.85 96.49 1.64 1.22 5.00 −0.53 −8.15 10,182.00 23.00 1127.00 3.99 717.60 52.80 38.25 13.24 0.1761
358.40 96.58 1.59 1.25 6.00 −0.73 −8.00 11,457.00 26.00 1613.00 1.70 739.00 43.40 38.28 13.41 0.2472
348.44 103.37 1.63 1.19 6.00 −0.75 −7.11 6088.00 26.00 1636.00 1.05 786.60 52.50 40.98 16.15 0.3259
334.41 98.53 1.66 1.25 6.00 −0.64 −7.02 10,981.00 25.00 1449.00 1.09 743.90 60.40 39.06 12.47 0.3600
348.44 102.94 1.62 1.19 6.00 −0.23 −7.14 8292.00 26.00 1657.00 1.22 783.30 51.80 40.81 17.30 0.2817
318.46 101.25 1.62 1.11 5.00 −0.26 −7.23 10,056.00 24.00 1251.00 2.20 757.00 48.50 40.14 14.55 0.2279
318.46 101.25 1.62 1.11 5.00 −0.26 −7.66 9204.00 24.00 1267.00 4.20 757.00 48.50 40.14 19.88 0.1605
350.45 104.96 1.61 1.16 6.00 −0.47 −7.74 12,252.00 26.00 1600.00 4.68 795.10 47.80 41.61 19.57 0.1662
359.29 101.39 1.65 1.29 5.00 −0.73 −8.15 9336.00 24.00 1267.00 1.95 753.50 53.80 40.19 14.74 0.2369
366.50 116.19 1.65 1.15 7.00 −0.04 −8.18 7878.00 28.00 2037.00 1.00 855.10 51.20 46.06 14.46 0.3259
373.53 116.42 1.63 1.14 7.00 0.35 −8.00 12,316.00 28.00 2037.00 3.25 881.60 53.10 46.15 19.06 0.1818
374.52 115.15 1.63 1.16 7.00 0.27 −8.07 8649.00 28.00 2037.00 2.89 869.70 52.80 45.65 18.99 0.2064
375.51 113.41 1.63 1.18 7.00 0.27 −8.09 15,751.00 28.00 2037.00 4.11 861.80 54.20 44.96 20.04 0.1693
391.57 119.97 1.66 1.20 7.00 0.20 −8.11 8044.00 28.00 2037.00 2.84 893.90 56.50 47.56 18.37 0.2238
300.35 92.48 1.66 1.20 6.00 −0.82 −8.46 10,636.00 23.00 1179.00 3.41 668.20 51.30 36.66 17.55 0.1953
316.35 94.33 1.66 1.24 7.00 −0.54 −8.26 10,540.00 24.00 1375.00 1.27 686.00 52.40 37.39 14.14 0.2419
315.37 97.26 1.70 1.26 7.00 −0.47 −7.10 10,636.00 24.00 1375.00 1.20 688.20 57.00 38.55 12.15 0.3010
306.40 93.75 1.62 1.15 7.00 −0.47 −8.30 15,751.00 24.00 1375.00 4.20 701.20 48.60 37.16 12.15 0.1647
321.42 97.23 1.64 1.19 6.00 −0.50 −7.73 9973.00 24.00 1287.00 4.90 733.10 54.80 38.54 19.35 0.1401
433.59 127.79 1.62 1.19 6.00 −0.40 −7.11 7968.00 32.00 2735.00 1.00 941.60 45.40 50.66 12.97 0.3126
431.61 131.01 1.62 1.15 6.00 −0.32 −7.11 8780.00 32.00 2735.00 4.20 961.10 44.40 51.93 8.41 0.3010
291.40 87.76 1.61 1.13 5.00 −0.67 −8.54 7892.00 22.00 990.00 1.30 676.10 46.60 35.46 10.04 0.3600
304.44 95.49 1.64 1.14 5.00 0.01 −8.92 11,435.00 23.00 1128.00 2.04 685.40 44.10 37.75 15.39 0.2419
333.48 102.63 1.59 1.12 6.00 0.36 −8.97 7867.00 25.00 1438.00 1.64 784.80 47.40 40.18 11.26 0.3259
292.39 86.66 1.65 1.21 5.00 −0.61 −8.23 7750.00 22.00 990.00 1.13 670.10 60.00 34.80 13.34 0.3126
291.40 87.81 1.64 1.18 5.00 −0.47 −8.00 9070.00 22.00 990.00 1.45 675.90 55.60 35.55 13.60 0.2908


































































































































































































































































































































































































































































































































00Fig. 3. Diagram of components in space after rotation.
3.2.  Principal  component  analysis  (PCA)
The first three principal axes were sufficient to
describe the information provided by the data matrix.
Indeed, the percentages of variance were 44.683%,
14.812% and 12.351% for the axes F1, F2 and F3,
respectively. The total information was estimated to a
percentage of 71.846%, and correlations between the 16
descriptors are shown in Table 4 and Fig. 3.
The matrix and correlation circle provides informa-
tion on the negative or positive correlation between
variables. The Pol, IW, RM, VM, Para and ClsC descrip-
tors were strongly correlated (r  > 0.95), so these variables
are redundant. Taking these observations into account,
we kept CLS and removed the other variables (Pol, IW,
RM, MV, Para).
3.3.  Descriptors  selection
The selected descriptors values and predicted activity
values obtained by the MLR, NN and CV methods are
summarized in Table 5.
3.4.  Multiple  linear  regression
The linear relationship between the activity data of
the studied compounds and their structure parameters
was fitted by MLR using 95% confidence intervals. To
propose a mathematical model and to quantitatively eval-
uate each substituent’s physicochemical effects on the
activity the entire set of 74 molecules, we submitted a
data matrix constituted obviously from the 17 variables
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Table 5
Values of the selected descriptors and the observed/predicted Y values.
ELUMO ClsC Log P EVDW YExp YMLR YNN YCV
Estimate Residual Estimate Residual Estimate Residual
−0.2152 22.0000 5.0515 12.9523 0.17 0.14 0.03 0.15 0.02 0.18 −0.01
−0.3199 22.0000 4.7388 11.0900 0.29 0.20 0.09 0.24 0.05 0.28 0.01
−0.1335 22.0000 1.3642 15.0010 0.29 0.27 0.02 0.28 0.01 0.27 0.02
−0.4790 16.0000 1.3776 8.7446 0.29 0.29 0.00 0.27 0.02 0.30 −0.01
−0.4819 16.0000 1.0649 7.1242 0.29 0.32 −0.03 0.29 0.00 0.31 −0.02
−0.1592 20.0000 2.0621 11.3359 0.20 0.25 −0.05 0.23 −0.03 0.26 −0.06
−0.3036 20.0000 1.0621 11.2019 0.27 0.28 −0.02 0.29 −0.02 0.30 −0.03
−0.4223 19.0000 1.2924 6.7410 0.28 0.31 −0.03 0.30 −0.02 0.31 −0.03
−0.3424 19.0000 1.2948 7.1330 0.27 0.30 −0.03 0.29 −0.02 0.31 −0.04
−0.2538 19.0000 1.1967 7.8294 0.28 0.30 −0.02 0.28 0.00 0.31 −0.03
−0.3928 22.0000 1.1838 11.8630 0.28 0.28 0.00 0.29 −0.01 0.30 −0.02
−0.6797 18.0000 1.0009 15.1316 0.30 0.29 0.01 0.30 0.00 0.28 0.02
−0.4108 18.0000 1.0968 8.9037 0.30 0.31 −0.01 0.29 0.01 0.30 0.00
−0.4982 18.0000 1.1668 8.9983 0.28 0.31 −0.03 0.29 −0.01 0.30 −0.02
−0.4078 17.0000 1.0507 7.9501 0.30 0.31 −0.01 0.29 0.01 0.31 −0.01
−0.8536 16.0000 1.4166 13.6791 0.27 0.28 −0.01 0.26 0.01 0.27 0.00
−0.2242 20.0000 1.1129 11.8569 0.29 0.28 0.01 0.29 0.00 0.29 0.00
−0.2416 21.0000 1.0020 12.8416 0.33 0.30 0.03 0.33 0.00 0.29 0.04
−0.3642 22.0000 5.1822 19.2232 0.14 0.12 0.02 0.15 −0.01 0.18 −0.04
−0.2733 18.0000 4.3823 10.6725 0.16 0.17 −0.02 0.16 0.00 0.21 −0.05
−0.7041 15.0000 1.0920 12.5573 0.31 0.29 0.02 0.29 0.02 0.29 0.02
−0.2046 15.0000 1.0620 9.7876 0.29 0.27 0.02 0.28 0.01 0.29 0.00
−0.6854 21.0000 4.9344 19.1117 0.16 0.15 0.01 0.13 0.03 0.19 −0.03
−0.8000 21.0000 1.6344 18.9608 0.29 0.26 0.03 0.26 0.03 0.25 0.04
−0.7301 21.0000 5.0344 18.9580 0.14 0.14 0.00 0.14 0.00 0.18 −0.04
−0.6551 20.0000 1.0501 9.7876 0.31 0.31 0.01 0.30 0.01 0.31 0.00
−0.8440 22.0000 4.7925 12.1931 0.29 0.22 0.07 0.29 0.00 0.27 0.02
−0.7972 20.0000 4.6161 16.2166 0.17 0.19 −0.02 0.17 0.00 0.23 −0.06
−0.6655 22.0000 1.1215 7.7939 0.36 0.35 0.01 0.36 0.00 0.32 0.04
−0.5644 23.0000 1.0690 9.7876 0.29 0.32 −0.03 0.33 −0.04 0.31 −0.02
−0.5839 22.0000 1.1917 17.7974 0.28 0.27 0.01 0.28 0.00 0.27 0.01
−0.9036 16.0000 1.0081 13.0424 0.33 0.31 0.02 0.31 0.02 0.29 0.04
−0.2287 22.0000 5.0118 15.8000 0.15 0.14 0.01 0.15 0.00 0.18 −0.03
−0.2999 22.0000 1.0395 9.7856 0.30 0.30 0.00 0.30 0.00 0.31 −0.01
−0.2335 23.0000 1.0891 14.5358 0.30 0.28 0.02 0.29 0.01 0.29 0.01
−0.2725 22.0000 1.0533 9.5350 0.31 0.30 0.01 0.30 0.01 0.31 0.00
−0.1837 23.0000 2.3698 9.5752 0.28 0.26 0.02 0.25 0.03 0.26 0.02
−0.2202 23.0000 5.1742 18.3317 0.15 0.15 0.00 0.15 0.00 0.25 −0.10
−0.7017 22.0000 4.9095 15.4440 0.17 0.19 −0.02 0.18 −0.01 0.22 −0.05
−0.4268 22.0000 3.8559 11.5106 0.20 0.22 −0.02 0.21 −0.01 0.22 −0.02
−1.1193 25.0000 1.6390 13.7559 0.30 0.31 −0.01 0.29 0.01 0.30 0.00
−0.2187 23.0000 4.4264 12.3111 0.17 0.19 −0.02 0.20 −0.03 0.23 −0.06
−0.1509 25.0000 3.0639 14.4341 0.19 0.21 −0.01 0.19 0.00 0.22 −0.03
−0.3648 26.0000 1.0010 11.6254 0.34 0.32 0.02 0.35 −0.01 0.31 0.03
−0.2778 23.0000 2.1163 13.5896 0.23 0.26 −0.03 0.23 0.00 0.25 −0.02
−0.2812 23.0000 1.9163 13.6806 0.23 0.26 −0.03 0.24 −0.01 0.26 −0.03
−0.4049 24.0000 5.8363 20.6863 0.14 0.11 0.03 0.13 0.01 0.18 −0.04
−0.5655 23.0000 1.8873 12.6689 0.24 0.28 −0.04 0.26 −0.02 0.27 −0.03
−0.5286 23.0000 3.9874 13.2425 0.18 0.22 −0.04 0.21 −0.03 0.21 −0.03
−0.7335 26.0000 1.7030 13.4128 0.25 0.29 −0.04 0.27 −0.02 0.29 −0.04
−0.7530 26.0000 1.0493 16.1467 0.33 0.31 0.01 0.33 0.00 0.30 0.03
−0.6418 25.0000 1.0862 12.4652 0.36 0.30 0.06 0.30 0.06 0.31 0.05
−0.2317 26.0000 1.2151 17.2978 0.28 0.27 0.01 0.29 −0.01 0.28 0.00
−0.2595 24.0000 2.2034 14.5464 0.23 0.25 −0.02 0.22 0.01 0.25 −0.02
−0.2601 24.0000 4.2034 19.8779 0.16 0.18 −0.02 0.14 0.02 0.20 −0.04
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Table 5 (Continued)
ELUMO ClsC Log P EVDW YExp YMLR YNN YCV
Estimate Residual Estimate Residual Estimate Residual
−0.4740 26.0000 4.6764 19.5699 0.17 0.17 −0.01 0.14 0.03 0.19 −0.02
−0.7266 24.0000 1.9456 14.7396 0.24 0.28 −0.04 0.26 −0.02 0.27 −0.03
−0.0365 28.0000 1.0044 14.4552 0.33 0.29 0.03 0.33 0.00 0.30 0.03
−0.3467 28.0000 3.2468 19.0600 0.18 0.22 −0.03 0.17 0.01 0.20 −0.02
−0.2710 28.0000 2.8925 18.9857 0.21 0.23 −0.03 0.21 0.00 0.21 0.00
−0.2659 28.0000 4.1145 20.0360 0.17 0.17 0.00 0.13 0.04 0.19 −0.02
−0.1992 28.0000 2.8363 18.3692 0.22 0.24 −0.01 0.22 0.00 0.22 0.00
−0.8150 23.0000 3.4130 17.5541 0.20 0.22 −0.02 0.17 0.03 0.20 0.00
−0.5405 24.0000 1.2748 14.1376 0.24 0.27 −0.03 0.27 −0.03 0.29 −0.05
−0.4661 24.0000 1.2027 12.1506 0.30 0.28 0.02 0.28 0.02 0.30 0.00
−0.4661 24.0000 4.2027 12.1506 0.16 0.19 −0.03 0.17 −0.01 0.20 −0.04
−0.4987 24.0000 4.9028 19.3512 0.14 0.17 −0.02 0.14 0.00 0.22 −0.08
−0.4037 32.0000 1.0044 12.9734 0.31 0.34 −0.02 0.30 0.01 0.32 −0.01
−0.3239 32.0000 4.2027 8.4120 0.30 0.28 0.02 0.31 −0.01 0.27 0.03
−0.6654 22.0000 1.3013 10.0405 0.36 0.31 0.05 0.31 0.05 0.31 0.05
−0.0075 23.0000 2.0389 15.3912 0.24 0.22 0.02 0.24 0.00 0.24 0.00
−0.3566 25.0000 1.6366 11.2647 0.33 0.30 0.03 0.31 0.02 0.29 0.04
−  0.02 0.30 0.01 0.30 0.01











ELumo LogP Cls C Evdw0.6127 22.0000 1.1344 13.3437 0.31 0.29
0.4674 22.0000 1.4487 13.6004 0.29 0.27
The most significant model with all descriptors hav-
ing P  < 0.05 is:
Y  =  0.297 −  0.050ELUMO +  0.004ClsC
− 0.030 log P  −  0.006EVDW
This method used the coefficients rMLR, r2, SD and
F-value to select the best regression performance
n  =  74rMLR =  0.88r2 =  0.79SD =  0.75F  =  65.217
where n is the number of compounds included in the
model, rMLR is the correlation coefficient, SD is the
standard deviation and F  is the Fisher F-statistic.
3.4.1. Contributions  of  the  selected  descriptors
The equation obtained by MLR shows that the ELUMO
(ELUMO values calculated are negative) and log P  val-
ues have a positive influence on activity, whereas the
ClsC and EVDW have a negative impact on the activ-
ity. Thus, for the synthesis of benzimidazole derivatives
with high activities, it is best to choose molecules having
favourable ELUMO, log P  and EVDW. The contribution of
the descriptors to this model is illustrated in Fig. 4.3.4.2. Correlation  between  YExp and  YMLR
The correlation coefficient between YExp and YMLR is
r = 0.89, meaning that the selected descriptors can form
a good QSAR-model.-0. 06
Fig. 4. Contributions of the selected descriptors to the QSAR model.
3.5.  Neural  network
To better characterize the studied compounds, neural
network (NN) analysis was used to generate a predictive
model of quantitative structure–activity relationships
(QSAR) between a set of molecular descriptors obtained
by MLR and the observed activities.
As shown in Fig. 5, a good correlation between YExp
values and YNN predicted activities was obtained (n  = 74,
rNN = 0.95, r2NN =  0.90). The graphical correlation of
observed and predicted Y  by NN is shown in Fig. 6.3.6.  Cross  validation
A QSAR model that is proposed to predict the activity
of new compounds should be validated before its use. We




















































According to the results shown in Table 5, the two
compounds 19  and 25  may be good drugs to activate





Calidated our model by a cross validation method using
he LOO procedure. The results (n  = 74; rCV = 0.90;
2
CV =  0.81) show the significant predictive power of
his model. Thus, the most important result of this inves-
igation is that biological activity can be predicted using
SAR methods and that the selected descriptors are
ertinent. The graphical correlation of observed and pre-
icted activity by CV is recorded in Fig. 7.able 6
ipinski parameters of compounds 19 and 25.




ompound 19 292.194 2 1 
ompound 25 270.116 2 1 Fig. 7. Correlation of observed and predicted activities calculated
using CV.
3.7.  Docking
To gain a better understanding of the activity of the
studied compounds, we explored the molecular dock-
ing of some benzimidazole derivatives to the AMPK
receptor. In this paper, we focused on the most active
compounds, 19  and 25. The binding modes of 19  and 25
are depicted in Figs. 8 and 9, respectively.
Further, VDW interactions are observed for both com-
pounds, and Thr256 and Thr264 are important binding site
residues involved in H-bond interactions with both com-
pounds 19  and 25. Additionally, the phenyl rings form
-cation interactions with ProB233 for both compounds,
while the Tyr263 residue interacts with compound 25
only.
3.8.  Test  of  Lipinski
A drug candidate that is likely to be orally active in
humans must possess remarkable biological activity and
comply to the Lipinski parameters [27]. These param-
eters are depicted in Table 6 for compounds 19  and
25.Log P preferably
−2 ≤ log P ≤ 5
Or more largely
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Fig. 8. Molecular docking modelling of compound 19 with AMPK. (A and B) 3D-model of the interaction between compound 19 and the AMPK
binding site. (C) 2D ligand interaction diagram of compound 19 with AMPK.
Fig. 9. Molecular docking modelling of compound 25 with AMPK. (A and B) 3D-model of the interaction between compound 25 and the AMPK



































[27] C.A. Lipinski, F. Lombardo, B.W. Dominy, P. Feeney, Experi-N. Naceiri Mrabti, M. Elhallaoui / Journal
.  Conclusion
In this paper, we have employed 3D-QSAR and
ocking techniques to explore the structure–activity rela-
ionship of a series of 74 benzimidazole derivatives to
valuate AMPK activators. The MLR and NN meth-
ds were used to build statistically significant models,
nd these were validated by a cross validation method
tilizing the LOO procedure. The models show good pre-
ictive capability for AMPK activators and could be used
o predict new AMPK activators. Molecular docking of
ompounds 19  and 25  with AMPK reveals important
ydrogen bonding interactions as well as electrostatic
nd VDW interactions. Furthermore, the Lipinski test
howed that compounds 19  and 25  have potential as
rugs. In the future, these QSAR models could provide
 reliable tool for the design of AMPK activators.
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